Evidence map›Paper›PMID 41428087›Full record

ArticleCancer immunology, immunotherapy : CII2025

FUBP3 mediates MXI1 stability to silence RRAS and hinder MAPK signaling in acute megakaryoblastic leukemia progression.

Ying Zhu, Jinying Liu, Jiqiang Zeng, Zhirui Liu, Zhimin Yan, Shanrong Zhang, Huixi Luo, Zhipeng Wu, Jiawei Lu, Fang Qiu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ying Zhu *Department of Blood Transfusion, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Jinying Liu *Basic Medical College of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Jiqiang ZengSchool of Medical Technology, Gannan Medical University, No. 1, Medical College Road, Ganzhou, 341000, Jiangxi, People's Republic of China.
Zhirui LiuState Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People's Republic of China.
Zhimin YanDepartment of Hematopathology, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Shanrong ZhangThe First Clinical Medical College of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Huixi LuoSchool of Nursing, Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Zhipeng WuThe First Clinical Medical College of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Jiawei LuThe First Clinical Medical College of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China.
Fang QiuDepartment of Blood Transfusion, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China. qf3914@163.com.
Junsong YeSubcenter for Stem Cell Clinical Translation, First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi, People's Republic of China. yjs1211@163.com.
Chen LuSchool of Medical Technology, Gannan Medical University, No. 1, Medical College Road, Ganzhou, 341000, Jiangxi, People's Republic of China. gzfylc@gmu.edu.cn.

Funding

Doctoral Research Initiation Fund of First Affiliated Hospital of Gannan Medical University DQ050Science and Technology Program of Ganzhou Science and Technology Bureau NO.GZ2023ZSF084 and NO.GZ2024YLJ147the Science and Technology Project of Health Commission of Jiangxi Province 202410332
6 · The paper itself

Abstract

RRAS, a gene encoding a small monomeric GTPase that controls cell adhesion and migration, has been linked to leukemogenesis. However, its function in acute megakaryoblastic leukemia (AMKL), a rare type of acute myeloid leukemia, remains indistinct. Here, we explored the potential and mechanism of RRAS in the immune escape of AMKL. Human AMKL cells M-07e and UT-7 were infected using lentiviruses and co-cultured with CD8

Indexed as

DNA-Binding ProteinsMAP Kinase Signaling SystemAnimalsCD8-Positive T-LymphocytesCell Line, TumorDisease ProgressionHumansMiceDNA-Binding ProteinsAcute megakaryoblastic leukemiaCD8+ T cellsFUBP3/MXI1MAPK signalingRRAS

Identifiers

PMID41428087
PMCPMC12722598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.